Mobia Medical Reports 102.4% Revenue Growth to $13.5 Million in Latest Quarter

Mobia Medical, Inc. reported significant financial growth in its latest quarterly filing, with revenues reaching $13.5 million for the three months ended June 30, 2026, a 102.4% increase from $6.7 million in the same period last year. For the six months ending June 30, 2026, the company generated $25.6 million in revenue, up 107.4% from $12.3 million in the prior year. The gross profit for the second quarter was $11.2 million, resulting in a gross margin of 83.2%, slightly up from 82.3% in the previous year. Despite this revenue growth, Mobia Medical reported a net loss of $21.0 million for the quarter, compared to a loss of $10.5 million in the same period last year, reflecting increased operating expenses primarily driven by higher selling, general, and administrative costs.

The company’s operational metrics indicate a strategic expansion, with a notable increase in customer engagement and product adoption. Mobia Medical's Vivistim Paired Vagus Nerve Stimulation System, which is designed for chronic ischemic stroke survivors, has seen a rise in units sold, contributing to the revenue increase. The company has also expanded its commercial organization, which has led to higher personnel-related expenses and marketing costs. As of June 30, 2026, Mobia Medical had cash and cash equivalents of $177.1 million, bolstered by a successful initial public offering (IPO) in May 2026 that raised approximately $134 million in net proceeds.

In terms of strategic developments, Mobia Medical underwent a corporate name change from MicroTransponder, Inc. in February 2026 and completed its IPO, which included a reverse stock split of 1-for-3.483. The IPO allowed for the conversion of all outstanding shares of redeemable convertible preferred stock into common stock, significantly altering the company’s capital structure. The company is focused on increasing awareness and adoption of the Vivistim System, which is currently marketed to primary and comprehensive stroke centers across the United States.

Mobia Medical's operational challenges include a material weakness in internal controls over financial reporting, specifically regarding the calculation of net loss per share. The company has implemented new controls to address this issue, which will be monitored for effectiveness. Looking ahead, Mobia Medical anticipates continued investment in its commercial organization and research and development efforts, aiming to expand its market presence and enhance its product offerings. The company expects to incur significant expenditures to support these initiatives, which may impact its financial performance in the near term.

Overall, while Mobia Medical has demonstrated strong revenue growth and strategic advancements, it continues to face challenges related to operational expenses and internal controls, which it is actively working to address as it seeks to establish itself as a leader in chronic stroke recovery solutions.